Biotalys Nv · EURONEXT:BTLS
Biotalys Nv — Investor Presentation (November 2026)
20 slides from Biotalys Nv's investor presentation, November 2026
Slide 1: From platform innovation to commercial impact
AGROBODY® biocontrols From platform innovation to commercial impact Launching EVOCA® NG in the US & EU in 2029 Carlo Boutton, CEO · Luc Van fraeyenhoven, CFO Public presentation · November 2026
Slide 2: Disclaimer
Disclaimer • This presentation (the “Materials”) has been prepared by the management of Biotalys NV (the “Company”). The Materials serve information purposes only and do not constitute a prospectus or any offer for sale or subscription of, or solicitation or invitation to buy or subscribe for, any s
Slide 3: Biotalys at a glance
Biotalys at a glance Precision biocontrols for sustainable crop protection Biotalys develops biological crop Spin-off from the Flemish Institute Experienced team protection against crop diseases for Biotechnology (VIB) Highly qualified and diverse team of 35 and pests Based in the Ghent biotech clus
Slide 4: EVOCA as frontrunner of the AGROBODY pipeline
EVOCA as frontrunner of the AGROBODY pipeline Infrastructure built for EVOCA cuts cost and time-to-market for BioFun-6 and beyond Research Discovery Development Deploy Botrytis & powdery EVOCA approved mildew EVOCA NG launch ’29 BioFun-6 launch ’31 Partnered programs and partnering opportunities Wha
Slide 5: The right biological, at the right time
The right biological, at the right time AGROBODY biocontrols arrive just as the chemical toolbox shrinks and the market moves to biologicals … and the market is pushing 1 Not all biologicals are equal… 2 3 … so, the window is now chemistry out… PUSH chemistry under pressure Resistance +15% vs +1.5%
Slide 6: Full execution to commercial launch in 2029 (US & EU)
Full execution to commercial launch in 2029 (US & EU) The Botrytis toolbox is emptying; EVOCA NG fills the gap, and the hard science is already done Major value inflection points achieved and technically derisked… … and now we execute Execution plan Unique MoA 100+ field trials Biotalys plans to bri
Slide 7: Growers are running out of tools to stop Botrytis
Growers are running out of tools to stop Botrytis EVOCA NG as novel and innovative rotation partner The current chemical Botrytis toolbox for fruit and vegetables LOW SAFE ZONE captan EVOCA NG +40% Resistance risk (loss of efficacy) fludioxonil1 of Botrytis strains are pydiflumetofen resistant again
Slide 8: EVOCA: a mode of action fungi haven’t seen
EVOCA: a mode of action fungi haven’t seen New FRAC class F10 → durable efficacy and low cross-resistance risk What is an AGROBODY? Llamas make simple and effective antibodies to fight off 1/10 Easy to diseases. We use the binding fragment of it: the the size of a normal Stable AGROBODY VHH. antibod
Slide 9: In the field, EVOCA performs on par with chemistry
In the field, EVOCA performs on par with chemistry 100+ greenhouse and field trials: swapping chemical sprays for EVOCA keeps Botrytis damage at chemical levels Company-driven trials Academic trials Partner’s trials explore and refine confirm performance validate and commit Example: EVOCA against Bo
Slide 10: Positive grower feedback in large-scale demonstration trials
Positive grower feedback in large-scale demonstration trials EVOCA applied in strawberries under exemption use in the Netherlands Brookberries EVOCA replaced a “EVOCA applied on 3.7 hectares of synthetic fungicide strawberries with great results” in the strawberry spray rotation program Noud Dings (
Slide 11: EVOCA is the first product of a platform
EVOCA is the first product of a platform From EVOCA to EVOCA NG and BioFun-6: from pilot product via “first in class” to “best in class” The AGROBODY platform EVOCA → EVOCA NG EVOCA NG → BioFun-6 Tackling Botrytis cinerea Optimising production €/kg g/ha Optimising use and dosing TODAY efficiency 1 E
Slide 12: Growers, distributors and retailers all benefit
Growers, distributors and retailers all benefit Chemistry-level efficacy, residue-free, biodegradable and competitively priced Efficacy Safety Cost per hectare Ease of use On par with chemical rotation partners in For consumer, grower and environment Priced in line with the chemical products Fits ex
Slide 13: A precise first market, with a large upside
A precise first market, with a large upside Top-down market sizing plus a bottom-up build: hectares × applications × price per ha × penetration Top 5 chemical Botrytis products in the market Global fungicide market Estimated annual market value (US+EU), $M: today’s leading chemical Botrytis products
Slide 14: EVOCA NG: expected milestones through 2029
EVOCA NG: expected milestones through 2029 Path to launch technically de-risked 2026 2027 2028 2029 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 EFSA conclusion EVOCA EU approval Bridging trials finished EVOCA NG 5-batch productions finished Regulatory tox studies Test production @CMO Tech transfer to CMO
Slide 15: First revenues expected in 2029
First revenues expected in 2029 Today’s P&L Current P&L, €M €M FY2025 HY2026 Other income 3.0 1.8 Aiming to achieve revenues similar to leading chemical External R&D (2.9) (1.9) products, which assumes: Salaries and compensation (10.1) (4.6) • EVOCA NG US & EU launch in 2029; BioFun-6 US launch in 2
Slide 16: How EVOCA NG grows: two levers
How EVOCA NG grows: two levers Continuous improvement lifts revenue and margin; Platform 2.0 opens new applications 1 Continuous improvement: rising revenue and margin from the same product Lower COGS Higher potency Smart combinations Broader use BioFun-6 Continuous process dose reduction, partially
Slide 17: From Platform 1.0 to Platform 2.0
From Platform 1.0 to Platform 2.0 Platform 1.0 proved the technology; Platform 2.0 targets more potent products, faster, as a continuous pipeline Platform 2.0 breaks the Platform 1.0 performance ceiling SINCE FOUNDING · PROVED THE TECHNOLOGY Platform 1.0 ↑ Product performance Platform 2.0 APPROACH S
Slide 18: An experienced and dedicated management team
An experienced and dedicated management team Strong expertise in innovation, crop protection and financing Management Carlo Boutton Luc Van fraeyenhoven Eva Van Hende CEO CFO Head of Regulatory & Sustainability 25+ years of experience in innovation with a 30+ years of experience in the biotech and 2
Slide 19: Support from shareholders with a long-term vision
Support from shareholders with a long-term vision Active follow-up by analysts 16,3% Others Analyst target prices: & free-float 40,0% €6.00 15,2% €5.70 11,4% 7,5% 9,9% €3.40 Shareholdings above 5%, based on the most recent transparency declarations to the company; shareholdings might have varied sin
Slide 20: Key highlights
Awards & recognition Independent recognition for our platform and products Key highlights 2026 Bernard Blum Award, Bronze EVOCA NG biofungicide · IBMA 1 The Botrytis toolbox is shrinking fast 2025 FoodTech 500 Ranked #32 worldwide · Forward Fooding 2 EVOCA brings a new mode of action with chemistry-